Background: The mechanism of maternal immune tolerance of the semi-allogenic
and self-antigens. 4 It consists of >95% of immunoglobulin G (IgG) and a few of immunoglobulin M, immunoglobulin A (IgA), several proteins, and albumin. After the first demonstration of the effectiveness of IVIg in immune thrombocytopenia purpura (ITP) in 1981, 5 it has been used widely in autoimmune and inflammatory diseases, such as ITP, Guillain-Barré syndrome, myasthenia gravis, corticosteroid-resistant dermatomyositis, Kawasaki's disease, graft-versus-host disease, and autoimmune uveitis. 6 Although the exact mechanisms of IVIg action have not been understood completely, intriguingly, IVIg not only has an anti-inflammatory effect, but also a pro-inflammatory effect.
Sometimes, it acts like an adaptor to innate immunity; IgGs bound to their specific antigens and promoting the humoral and cellular immune response of the innate immune system via activation of the complements and binding to Fcγ receptors (FcγRs) on various immune cells.
On the contrary, IVIg regulates pathogenic autoimmunity in animal models, such as K/BxN arthritis, nephrotoxic nephritis, and skin-blister diseases. 7 Thus, IVIg has drawn attention as an immune modulator for various immune disturbances and this review focuses on the immune regulatory effect of IVIg in RF.
| IMMUNE MODULATION OF I.V. IMMUNOGLOBULIN G
The 
| Structure of immunoglobulin G and its receptors on immune cells
Immunoglobulin G comprises two identical light chains and two identical heavy chains. Both the light and the heavy chains consist of amino-terminal variable regions that participate in antigen recognition and carboxyl-terminal constant regions. Immunoglobulin G is divided into a F(ab')2 fragment that contains two antigenbinding sites and one Fc fragment. 8 The F(ab')2 fragment is the antigen-binding sites of IgG binding to foreign and self-antigens.
Intravenous immunoglobulin G has demonstrated immune modulatory effects via the F(ab')2 fragment in both antigen-specific and antigen-non-specific ways. 
| Effect of i.v. immunoglobulin G on dendritic cells
Intravenous immunoglobulin G at a physiologic concentration, 12-14 mg/mL of human plasma, suppresses the differentiation and maturation of dendritic cells (DCs) from monocytes. 9 As a result, the expression of major histocompatibility complex (MHC) class II and costimulatory molecules, such as CD80 and CD86, decrease on the DC. which induces NK cell cytotoxicity that is called "antibody-dependent cell-mediated cytotoxicity" (ADCC). 8 The expression of this activating
FcγRIIIA on NK cells and myeloid cells was down-regulated following
IVIg administration in mice and humans. 21, 22 On the contrary, IgG dimers and multimers, but not monomers, in
IVIg can make a bridge between FcγRII on NK cells and DCs, which lyses DCs. animal models. 17, 25, 26 However, the expression of the interferon-gamma receptor on the FcγRIIIB + macrophage was suppressed by IVIg. 
T A B L E 1 Fc receptors (FcRs) on the immune cells

| Effect of i.v. immunoglobulin G on T cells
In a study with ITP in children, IVIg brought stable remission by skewing type 1 cytokine-producing T helper cells (Th1)-mediated immunity to type 2 cytokine-producing T helper cells (Th2)-mediated immunity. 27 Intravenous immunoglobulin G inhibits cytokine production and the proliferation of human T cells as effectively as cyclosporine or tacrolimus. 28 However, the action of IVIg on conventional T cells is still unknown. 
| Effect of i.v. immunoglobulin G on regulatory T cells
There is obvious evidence that IVIg expands T reg cells and strengthens their suppressive function. 32, 34 A study demonstrated that the addition of IVIg to a T reg cell culture system significantly increased the expression of forkhead box (Fox)p3, IL-10, and transforming growth factor (TGF)-β and stimulated the suppressive function of the T reg cells in order to inhibit TGF-α. 34 However, the exact mechanism of IVIg on (Figure 2 ). In the same study, Th2 immunity in allergic patients turned into Th0 and Th1 immunities following IVIg treatment. 
| Effect of i.v. immunoglobulin G on interleukin-17-producing T-helper 17 cells
The addition of IVIg to a human CD4 + T cell culture system inhibited the differentiation and expansion of Th17 cells. and SIGLEC8, expressed on eosinophils, which deplete neutrophils and eosinophils, thus contributing to the down-regulation of tissue inflammation. 7 The F(ab')2 fragments in IVIGs also can react to the activated complements, C3a and C5a, and neutralize them so as to not activate immune cells. 
| Effect of i.v. immunoglobulin G in unexplained recurrent pregnancy losses
Although the range of "unexplained RPLs" is not exactly the same in each study, most of the investigators defined it as a RPL without classically proved etiologies, such as genetic, anatomic, infectious, and endocrine factors, or antiphospholipid syndrome (APS). One study insisted that about half of women have unexplained RPLs and a certain part of unexplained RPLs is contributed to by non-APS thrombophilias and immunologic causes. 53 It was first proposed in 1986 that IVIg treatment in 20 patients with unexplained RPLs had promising results 54 and following pilot studies also described favorable pregnancy outcomes with IVIg in women with RPLs. 55, 56 Furthermore, it was proven in an abortion-prone mouse model. 57 However, since then, a controlled double-blind study was performed by the same authors that failed to prove the clinical effect of IVIg in women with RPLs 58 and a recent meta-analysis with eight randomized controlled trials (RCTs)
showed no significant benefit of IVIg in the pregnancy outcomes of unexplained RPLs. 59 These insights have stimulated attempts to find the right indications for IVIg for RPLs. One study suggested that to find modifiable immunologic abnormalities with IVIg is important for the appropriate use of IVIg for RPLs.
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| Effect of i.v. immunoglobulin G in recurrent pregnancy losses and repeated implantation failure with cellular immune abnormalities
Compared to normal fertile control, an elevated NK cell proportion and its cytotoxicity and elevated Th1 and Th17 cytokine production have been reported in women with RPLs and/or repeated implantation failures (RIFs). [63] [64] [65] [66] Intravenous immunoglobulin G has shown significant regulatory effects on abnormal NK cell proportions and its cytotoxicity and Th1/Th2 cytokine ratio. 50, 67, 68 According to a recent study, an elevated Th17/T reg ratio in RPLs also could be regulated with IVIg. 63, 69 Based on these results, IVIg was used in patients with RPLs or RIFs with these cellular immune abnormalities and many observational studies reported favorable pregnancy outcomes. 50, 67, [70] [71] [72] The authors' previous study also demonstrated a significantly higher live birth rate using without a cellular immunologic test (86.8% vs 65%) (Figure 3) . 73, 75 In addition, the live birth rate of the women with RPLs with cellular immune abnormalities after IVIg treatment was comparable with that of the women with RPLs without cellular immune abnormalities (84.7% vs 89.7%). 73 Another study in the unexplained infertility of patients with RPLs or RIFs and cellular immune abnormalities showed significantly improved outcomes in the IVIg-using group than the non-using group. 76, 77 However, most studies to date are limited, with relatively small study populations, and there is not a large amount of data available about the natural course of RPLs with cellular immune abnormalities yet.
Unexplained infertility, which remains unknown even after a systemic infertility work-up, and RIFs, even after good embryo transfers over three times, have been considered to share a common part of their etiology with RPLs. 41, [78] [79] [80] [81] [82] [83] Various remedies for RPLs also were tried in unexplained infertility and RIFs and most of them are immunemodulating agents. Intravenous immunoglobulin G also has shown favorable results for RIFs and unexplained infertility with cellular immunologic disturbances. 70, 76, 77, 84 
| Effect of i.v. immunoglobulin G in recurrent pregnancy losses with antiphospholipid syndrome and other autoimmune diseases
Antiphospholipid syndrome is characterized by antiphospholipid antibodies, such as lupus anticoagulant (LAC), anticardiolipin andibodies, and/or anti-β2-glycoprotein I antibodies, and causes pregnancy losses or thrombo-embolic events. 85 At first, prednisone was applied to women with pregnancy losses from APS. However, maternal and fetal complications from the corticosteroid lead researchers to find alternative regimens and low-dose aspirin combined with prophylactic-dose heparin has been regarded as the reasonable treatment for RPLs with APS to date.
One study first described the neutralization of LAC through idiotype/antiidiotype interaction and successful pregnancy outcomes after IVIg infusion in a patient with RPL with LAC. 86 Based on this mechanism (neutralization of the autoantibodies), IVIg was tried and resulted in live births, especially in those whom had never gotten a live birth with any other remedy without IVIg. [87] [88] [89] Another study described that IVIg can be a possible additional or alternative therapy in patients with refractory APS with other medications, such as heparin and low-dose aspirin, or in women who have side-effects or contraindications to heparin and/or aspirin. [90] [91] [92] However, IVIg cannot be a first-line therapy for RPLs with APS. 93, 94 Although numerous efforts have been made, there is no supportive RCT about IVIg that was used in RPLs with autoantibody-mediated autoimmune diseases yet. 70 Recently, one article described a healthy live birth and complete regrowth of the patient's hair by using IVIg in a woman with RPLs with Hashimoto's thyroiditis, which is known as an antithyroid antibody that is mediated by destructive thyroid disease, accompanied by alopecia totalis. (Table 2) . 94 According to the guideline, IVIg treatment is indicated in women with RPLs or RIFs and with cellular immune abnormalities, based on the following tests: (i) peripheral blood NK cell proportion; (ii) its cytotoxicity; and (iii) Th1/Th2 cytokine cell ratio.
| Safety of i.v. immunoglobulin G in patients with reproductive failure
Anaphylactic reaction immediately after IVIg was reported in IgAdeficient (<7 mg/dL) patients and the sugar stabilizer of IVIg is associated with renal insufficiency after high-dose IVIg treatment. [100] [101] [102] Therefore, every patient should have blood tests for their serum
IgA level and blood creatinine before IVIg administration. Mild sideeffects, such as fever, malaise, myalgia, and headache, have been reported in 4% of patients and most of them were tolerable.
103
There has been no report of serious adverse effects after the use of IVIg in neonates. 104, 105 Antenatal IVIg use for fetal neonatal alloimmune thrombocytopenia was not associated with premature maturation or other unusual reactions of the neonatal immune system. 106 To date, there has been no report with significant side-effects in the mother and the baby in those using IVIg prior to conception and during pregnancy for the last 20 years in this field. However, the number of published studies regarding the safety for the baby after intrapartum IVIg therapy is small. 
| SUMMARY
